Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Sectornieuws - biotech

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,743 14 jun 2024 17:35
  • -0,007 (-1,00%) Dagrange 0,743 - 0,759
  • 2.937.440 Gem. (3M) 6M

Sectornieuws - biotech

6.458 Posts
Pagina: «« 1 ... 90 91 92 93 94 ... 323 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 maart 2014 11:23
    Fundamentals vs. Market perception
    Fundamentals should drive market sentiment and share price of a company. However, often the reverse also occurs. The share price dictates the sentiment that is contradictory to fundamentals.

    Both ALN-TTR02 and –TTRsc will be successful in treating both FAP and FAC in future. But in view of the recent Barclays webcast presentation by L. Reid, our CBO, the third drug candidate, ALN-AT3 alone has a great value. I picked this drug because its coagulation cascade control appears robust (will post in another occasion), and its commercial value is visible from #19 of the presentation slides, which contains the following information.

    There are more than 40,000 Hemophilia A patients (Loss of function in Factor VIII) and greater than 9500 Hemophilia B (Loss of function in Factor IX) both in US and EU. ALN-AT3 may not be initially used as a first line of treatment. Some of these hemophilia patients become non-responsive to recombinant Factor VIII or IX (from immune attack against the treatment). There are 6000 such “inhibitor” patients and 1000 RBD(rare bleeding disorder) patients worldwide and 2000 in major markets for inhibitor patients.

    There is no good treatment for these 2300 patients in major markets. They go through greater than 5 hospitalization per year costing 300 K per year per “inhibitor” patient on average, and up to $1M for some. This is a high unmet medical need. If Alnylam management decided to provide AT3 at an annual cost of 150 K, a half the current cost, does it not provide a great service to the society? It would represent medical cost savings of $345 million dollars, mostly for tax payers. When some of remaining 48,000 patients can be treated, the societal savings would only increase because Alnylam can afford to lower the drug price. Some will still argue that the price is still too high. Reid says the market size is 9 B, and Biogen CEO says 7 B. Compared to this figure, a 150 K price tag per year for inhibitor patients looks cheap. The potential values of ALN-AT3 and ALN-CC5 together would more than justify the current market cap.
  3. forum rang 10 voda 25 maart 2014 23:16
    Kan Facebook dit Pharming VR bedrijf ook niet overnemen? :-)

    Facebook stapt in virtual reality

    DINSDAG 25 MAART 2014, 22:46 uur | 37 keer gelezen

    MENLO PARK (AFN) - Facebook neemt het 'virtual reality'-bedrijf Oculus VR voor 2 miljard dollar (circa 1,5 miljard euro) over. Dat maakte het bedrijf achter het populaire sociale netwerk dinsdag bekend.

    Facebook betaalt 400 miljoen dollar in contanten en rekent de rest af via de overdracht van ruim 23 miljoen eigen aandelen. Daar kan in totaal nog 300 miljoen dollar in aandelen en contanten bijkomen als bepaalde mijlpalen worden gehaald.

    Oculus is onder meer producent van speciale brillen waarmee gamers volledig kunnen opgaan in een spel. Facebook wil de capaciteiten van het bedrijf uitbouwen, zodat de technologie ook kan worden gebruikt op het gebied van communicatie, media, onderwijs en entertainment. De ontwikkelingen op die gebieden staan volgens Facebook nog in de kinderschoenen.

    “Oculus heeft de mogelijkheid het meest sociale platform ooit te bouwen en de manier waarop we werken, spelen en communiceren te veranderen”, zei Facebook-topman Mark Zuckerberg over de overname. Facebook kocht vorige maand nog de internetberichtendienst WhatsApp voor 16 miljard dollar.

  4. forum rang 10 DeZwarteRidder 26 maart 2014 18:25
    Epigenomics-Aktie: Gespanntes Warten auf die FDA-Experten

    Autor des Textes: Michael BarckAutor: Michael Barck auf google+ folgen!

    Nachricht vom 26.03.2014 26.03.2014 (www.4investors.de) - Die Epigenomics-Aktionäre schauen am heutigen Mittwoch über den Atlantik. In den USA trifft im Tagesverlauf ein Expertenkomitee der Behörde FDA zusammen. Man wird über den Zulassungsantrag beraten, den Epigenomics für den blutbasierten Darmkrebstest Epi proColon gestellt hat. Eine US-Zulassung wäre ein enorm wichtiger Meilenstein für das Biotechunternehmen, das am Freitag seine Bilanz für das vergangene Jahr vorlegen wird. Die Ergebnisse des FDA-Gremiums werden richtungweisend sein, aber nicht entscheidend. Die US-Behörde ist an das Votum des Ausschusses nicht gebunden, oftmals folgt man aber dem Rat des Komitees.

    Nach dem gestrigen Schwächeanfall erholt sich der Epigenomics-Aktienkurs im heutigen Handel deutlich. Gestern hatte das Papier ein massives charttechnisches Verkaufssignal an der Unterstützung bei 7,77/7,92 Euro generiert, die per Gap zwischen 7,65 Euro und 7,85 Euro unterschritten wurde. Das hatte einen Kurssturz bis auf 7,07 Euro ausgelöst, das gestrige Tagestief liegt 2 Cent darunter und damit direkt an der weiter steigenden 20-Tage-Linie, die bei ebenfalls 7,05 Euro notiert. Von hier ist der Epigenomics-Aktienkurs nach oben abgeprallt. Am Mittwochvormittag gegen 11 Uhr notiert die Aktie bei 7,50 Euro mit Aktienkursgewinne 6,12 Prozent im Plus.

    US-Expertenkomitee der FDA tagt zu Epi proColon

    Die Charttechnik bleibt interessant: Zunächst ging es im heutigen Handel von 7,25 Euro auf 7,65 Euro nach oben, womit das Papier aber zunächst am gestern aufgerissenen Gap nach unten abgeprallt. Unterhalb von 7,45 Euro beginnt eine Unterstützung, die bis an das heutige Tagestief um 7,25 Euro reicht. Allerdings könnten die Nachrichten aus den USA, die anstehen, die charttechnischen Szenarien kurzfristig in den Hintergrund stellen – egal wie das Votum der Experten nun ausfallen wird.
  5. [verwijderd] 30 maart 2014 11:33
    Bayer to invest more than 500 million euros to expand haemophilia A drug production
    (Ref: The Wall Street Journal, PR Newswire, Yahoo!Finance)
    March 11th, 2014
    By: Joe Barber
    Tags: Top Story BAY 81-8973 BAY 94-9027 Kogenate FS Bayer Corporate Affairs

    2
    inShare

    Email
    Print
    Bayer on Tuesday said that it would invest more than 500 million euros ($694 million) in two German facilities to expand production capacity for recombinant factor VIII (rFVIII) products currently under development for the treatment of haemophilia A. The company indicated that the investment will result in the creation of about 500 jobs at the sites in Wuppertal and Leverkusen by 2020.

    "This investment will be one of the largest in the history of Bayer HealthCare and reflects our strong commitment in the field of haemophilia A," remarked Bayer HealthCare CEO Olivier Brandicourt. The drugmaker noted that the investment will also create a new supply source for its haemophilia A product Kogenate, which is currently manufactured solely at a plant in California. Bayer commented that the additional production capacity is necessary ahead of the introduction of new therapeutic options as well as growing demand for haemophilia A therapies.

    The company is developing the plasma protein-free rFVIII BAY 81-8973, which is an upgrade of Kogenate, as well as the long-acting rFVIII BAY 94-9027. Both therapies are in late-stage development and Bayer announced last month that BAY 94-9027 protected against bleeding events in patients with haemophilia A while requiring fewer injections. The drugmaker aims to file BAY 81-8973 for regulatory approval in the second half of 2014 with the first launches planned in the fourth quarter of 2015, while Bayer plans to seek clearance of BAY 94-9027 in the second half of 2015.
  6. [verwijderd] 31 maart 2014 09:56
    FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B

    March 28, 2014 -- The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

    Alprolix is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of bleeding episodes (prophylaxis). Alprolix consists of the Factor IX molecule linked to a protein fragment, Fc, which is found in antibodies. This makes the product last longer in circulation.

    “The approval of this product provides another therapeutic option for the treatment and prevention of bleeding in patients with Hemophilia B,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

    Hemophilia B is an inherited sex-linked, blood-clotting disorder, which primarily affects males, and is caused by defects in the Factor IX gene. Hemophilia B affects about 3,300 people in the United States. People with Hemophilia B can experience repeated episodes of potentially serious bleeding, mainly into the joints, which can be destroyed by the bleeding.

    The safety and efficacy of Alprolix were evaluated in a multi-center clinical trial that compared each of two prophylactic treatment regimens to on-demand treatment. A total of 123 individuals with severe Hemophilia B, ages 12-71, were followed for up to a year and a half. The studies demonstrated the effectiveness of Alprolix in the prevention and treatment of bleeding episodes and during perioperative management of patients undergoing a surgical procedure. No safety concerns were identified in this trial.

    Alprolix received orphan-drug designation for this use by the FDA because it is intended for treatment of a rare disease or condition.

    Alprolix is manufactured by Biogen Idec, Inc., Cambridge, Mass.

    Source: FDA

    Posted: March 2014
  7. [verwijderd] 31 maart 2014 10:50
    Dyax Reports Full Exercise of Underwriters' Option to Purchase Additional Shares
    March 31, 2014

    Dyax Corp. announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,200,000 shares of Dyax's common stock at a price to the public of $9.25 per share, less customary underwriting discounts and commissions.

    In a release, the Company said that the net proceeds of approximately $10.4 million from the exercise of the option brings the aggregate net proceeds from the offering to approximately $80.0 million, after deducting the underwriting discount and other estimated offering expenses payable by Dyax. The additional shares were delivered to the underwriters on March 25.

    Jefferies is acting as the sole book-running manager for the offering. Cowen and Company is acting as the co-lead manager, with Wedbush PacGrow Life Sciences, Needham & Company and Oppenheimer & Co. Inc. acting as the co-managers.

    As previously announced, Dyax said that it intends to use the net proceeds from this offering for global development of DX-2930 for the prophylactic treatment of HAE, research and development of product candidates, including DX-2930, to address other plasma- kallikrein-mediated disorders, and general corporate purposes. Additionally, proceeds from this offering may be used to prepay some or all of the debt to HealthCare Royalty Partners (HCRP), which would enable Dyax to use cash flow from its Licensing and Funded Research Portfolio (LFRP) to fund the research and development efforts referenced above. Dyax will retain broad discretion to allocate the proceeds.

    A registration statement relating to the shares of Dyax common stock being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at sec.gov.
  8. forum rang 10 voda 31 maart 2014 16:31
    Johnson & Johnson akkoord met bod Carlyle

    MAANDAG 31 MAART 2014, 14:22 uur | 194 keer gelezen

    NEW BRUNSWICK (AFN) - Johnson & Johnson (J&J) heeft het overnamebod van investeringsmaatschappij Carlyle op het onderdeel Ortho Clinical van 4 miljard dollar (2,9 miljard euro) geaccepteerd. Dat maakte het Amerikaanse bedrijf maandag bekend.

    Carlyle kondigde in januari aan Ortho Clinical over te willen nemen. Dat onderdeel houdt zich bezig met bloed- en cholesterolonderzoek en werd vorig jaar in de verkoop gezet. Volgens J&J werd de goedkeuring voor de verkoop gegeven na overleg met de ondernemingsraad en de vakbonden.
  9. forum rang 10 voda 1 april 2014 16:05
    Galapagos rondt verkoop divisies Argenta en BioFocus af

    AMSTERDAM (Dow Jones)--Galapagos nv (GLPG.BT) heeft de verkoop van zijn servicedivisies BioFocus en Argenta aan Charles River Laboratories International voor een totaalbedrag van maximaal EUR134 miljoen afgerond, meldt het biotechbedrijf dinsdag.

    Galapagos heeft reeds EUR129 miljoen ontvangen, waarmee de kaspositie van het concern rond de EUR248 miljoen ligt. De overig EUR5 miljoen ontvangt het bedrijf na 12 maanden, afhankelijk van het bereiken van een vooraf bepaalde omzetdoelstelling.

    Vanwege de desinvestering verwacht Galapagos dat de omzet dit jaar zal dalen tot EUR125 miljoen van EUR180 miljoen en rekent op een kaspositie aan het einde van het jaar van EUR170 miljoen.

    - Door Levien de Feijter, Dow Jones Newswires; +31 20 571 52 00; levien.defeijter@wsj.com


  10. forum rang 10 DeZwarteRidder 3 april 2014 15:23
    Avivagen Announces Poultry Trial Agreement with Chonbuk National University of Korea
    Posted on March 31, 2014

    Ottawa, ON – Avivagen Inc. announces an agreement with Chonbuk National University of the Republic of Korea (South Korea) to conduct a trial of OxC-beta for the prevention of a commercially important poultry disease.

    The trial will test the efficacy of OxC-beta for the prevention of morbidity and mortality resulting from the poultry pathogen Clostridium perfringens. This bacterium causes intestinal damage in chickens, leading to reduced feed conversion economics, clinical illness and deaths. It is a troubling bacterial issue in worldwide poultry production and a frequent reason for the prophylactic or therapeutic use of antibiotics in feeds. This bacterium also causes disease in humans; leading to “food poisoning” if ingested and “gas gangrene” if introduced into wounds.

    The trial is entitled “Preventative Effect of OxC-beta on Necrotic Enteritis Model with Broiler Chickens.” It will have five study arms: testing two clinically and commercially relevant dosages of OxC-beta against two commercial Antibiotic Growth Promoters (AGPs) and a negative control group. The trial will first reconfirm the optimal dose level of OxC-beta in this challenge model and then conduct two parallel repeats of greater statistical-significance.

    The trial was designed by Professor Jang Hyung-Kwan, of the College of Veterinary Medicine of Chonbuk National University of Korea, Professor William Riley of Jinan University of Guangzhou, China and Avivagen executives. The trial will be conducted by Professor Jang at Chonbuk and the full protocol is targeted to conclude in the first quarter of calendar 2015.

    Cameron Groome, CEO and President, commented on Avivagen’s objectives for this trial:

    “Professor Jang has developed an elegant and efficient Clostridial challenge model, and we are pleased to be working with him, Chonbuk and our Korean distributor on this study. It is our hope that this study will provide results to support national registrations for this poultry indication while also emulating the result of a previous trial with OxC-beta against this pathogen.”

    Cameron also discussed the various studies being established:

    “Avivagen-sponsored OxC-beta studies are important as they may provide publishable results in support of national product registrations. This second Avivagen-sponsored trial is in addition to trials designed and run by prospective commercial customers, some of which are ongoing and others that are in the planning stages. However, unlike Avivagen-sponsored trials, any positive results of customer-sponsored OxC-beta trials might not be reported other than by way of product sales.”

    About Avivagen Inc.
    Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV”. The Company’s goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen’s targeted markets include Livestock Productivity and Pet Wellness.

    The company has sites located in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island. More information can be found at www.avivagen.com.

    About OxC-beta
    Avivagen’s proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body’s own systems to maintain and enhance health, particularly by supporting immune function. Avivagen’s commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

    Research and study results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

    The commercial products of Avivagen are OxC-beta for livestock, Vivamune™ Health Chews and Oximunol™ Chewables.
  11. forum rang 10 DeZwarteRidder 4 april 2014 08:22
    Positive Panel, but 3 Risks Remain for MannKind Corporation

    By Brian Orelli | More Articles
    April 2, 2014 | Comments (21)

    I was on the right side of the coin, but missed by a wide margin the magnitude that the Food and Drug Administration advisory committee would approve MannKind's (NASDAQ: MNKD ) inhaled insulin Afrezza.

    After the documents from the FDA came out on Friday, I suggested Afrezza might "squeak by with a positive recommendation from the panel." The vote was 13-1 in favor of approval for type 1 diabetes and 14-0 for type 2 diabetes.

    That's far from a squeak.

    Investors shouldn't forget that the FDA has the final say. It's hard to see the agency going against such a strong vote of confidence, but there is some precedence. The FDA rejected Merck's sugammadex -- back when it was owned by Schering-Plough -- after an advisory committee unanimously approved the drug. Over five years later, Merck still hasn't been able to get the drug approved.

    At this point, there are three things that could keep MannKind from getting approved on April 15, the FDA's goal for making a decision.

    1. It's only two weeks away
    That may not be long enough time for the FDA to incorporate the committee members' comments into the label and work out post-marketing requirements with MannKind. The FDA has a couple of options. It could just ignore the goal since it's not an official deadline and take a couple of weeks to make its decision or it could issue a three-month extension.

    Either way, it's a minor issue for MannKind. It was running low on cash, but has shares that it can sell in the open market if it hasn't done so already. Worse comes to worst, its billionaire namesake, CEO Al Mann, can cut the company a loan.

    Source: MannKind.

    2. There's still the conversion issue
    MannKind made a change to the injected-inhaled insulin conversion between the clinical trials and the recommendation for the label. The conversion is important for type 1 diabetics switching from Eli Lilly's (NYSE: LLY ) Humalog or Novo Nordisk's (NYSE: NVO ) Novolog to Afrezza. The change obviously wasn't a big enough deal to affect committee members' votes -- or the difference between pharmacokinetic and pharmacodynamics went over their heads -- but the FDA was clear in its briefing documents and during its presentation to the committee that the new conversion was unacceptable.

    It seems to me that MannKind is going to have to change back to the conversion used in the clinical trials or run a pharmacodynamics study to get the new conversion approved. In theory this shouldn't affect type 2 diabetics that are new to insulin, so the FDA could approve Afrezza for type 2 diabetics while MannKind ran a pharmacodynamics study on type 1 diabetics.

    3. Risk-benefit analysis
    There were no major safety issues revealed by the FDA, which was the biggest risk going into the advisory committee meeting since investors had only seen top-line data. But the FDA highlighted multiple times that the effects of Afrezza were "modest" compared to other diabetes treatments. Drugs with modest effects can still get approved, but they need squeaky-clean safety profiles.

    For Afrezza, the concern is with putting a drug in the lungs that doesn't treat lung disease. The FDA is worried about lung cancer and potentially decreasing lung function over time. Both are hard to definitively rule out in a clinical trial designed to get a drug approved.

    While all except one committee member ultimately believed the benefits outweighed the risk, many still expressed concerns about safety in their comments during the committee meeting. The FDA considers the comments as much, if not more, than it does the final vote. If MannKind had squeaked by with a positive vote, I'd argue the FDA might go against the committee like we saw with Orexigen's obesity drug Contrave. The committee voted 11-8 recommending approval, but the FDA rejected Contrave anyway.

    With a near-unanimous recommendation for approval, it seems less likely -- though not impossible -- the agency will go against the committee's risk-benefit evaluation. More likely, the FDA will ask MannKind to run post-marketing studies to look at lung safety.

    So will it get approved?
    I think an approval on or before April 15 is unlikely because it takes time to cross the t's and dot the i's. The conversion issue has to be worked out. It's a fixable problem, but might result in a delay, at least for type 1 diabetes.

    The big unknown is how the FDA will treat the lung safety issues. I certainly hope the FDA approves Afrezza. What's the point in holding advisory committee meetings if the agency is just going to ignore its outside advisors? But the FDA marches to the beat of its own drum and investors should factor in the potential for a surprise rejection especially given the FDA's tempered view of the efficacy data.
  13. forum rang 7 lucas D 4 april 2014 13:12
    'Miljardenovername in farmacie in de maak'

    NEW YORK (AFN/BLOOMBERG) - De Amerikaanse medicijnenfabrikant Mylan overweegt een miljardenbod op zijn Zweedse branchegenoot Meda. Dat meldden diverse media op basis van ingewijden.

    Meda bevestigde vrijdag dat er met Mylan wordt gesproken. De onderhandelingen zouden echter nog in een pril stadium zijn, waardoor het nog niet duidelijk is of er daadwerkelijk een overeenkomst kan worden bereikt.
  14. forum rang 10 voda 7 april 2014 16:41
    ‘3 aantrekkelijke Belgische midkappers’

    MAANDAG 7 APRIL 2014, 09:24 uur | 3048 keer gelezen

    De BEL-MID index heeft beleggers dit jaar geen windeieren gelegd. Met een winst van ruim 7 procent sinds de start van dit jaar, doet de index het beter dan veel andere Europese indices. Beursduivel sprak met Peter Berger van Beursplein6 over de aantrekkelijkheid van de Belgische index, en drie interessante koopkandidaten.

    De Belgische midkap doet het al een tijdje goed, zit er nog meer in het vat?

    'Dat denk ik wel, want op aandelenniveau zijn er zeker nog aandelen die op dit moment op aantrekkelijke waarderingen staan, met mooie groeivooruitzichten. Natuurlijk zijn niet alle aandelen uit de index koopwaardig, maar een groot gedeelte van de aandelen uit de midkap zijn dat wel.'

    Waar denkt u aan?

    Zijn er nog andere aandelen die nu aantrekkelijk zijn?

    ‘Ik kijk dan vooral naar de farmaceutische hoek. Zo zie ik in Galapagos nog altijd een koopkans. Galapagos is overigens wel een bedrijf met wat meer risico. Als het auto-immuunmedicijn bijvoorbeeld niet wordt goedgekeurd, kan dat leiden tot een forse koersval van het aandeel. Maar in vergelijking met de upside die het aandeel heeft als het medicijn wél wordt goedgekeurd, zie ik in Galapagos nu een aantrekkelijk aandeel. Het risico aan de onderkant wordt bovendien beperkt door de andere projecten die nu bij Galapagos lopen.’

    Voor hele artikel, zie link:

    www.belegger.nl/nieuws/2648892/3-aant...
  15. forum rang 10 voda 7 april 2014 17:24
    Miljardenfusie in farmaciebranche in de maak

    MAANDAG 7 APRIL 2014, 17:16 uur | 20 keer gelezen

    DUBLIN (AFN) - Het Ierse farmacieconcern Mallinckrodt wil fuseren met zijn Amerikaanse branchegenoot Questcor. De twee ondernemingen hebben overeenstemming bereikt over een overname waar in totaal van 5,6 miljard dollar (4,1 miljard euro) mee is gemoeid, zo maakten zij maandag bekend.

    Per aandeel Questcor komt het bod neer op 86,10 dollar, waarvan Mallinckrodt 30 dollar in contanten zal voldoen en de rest in eigen aandelen. Na afronding van de deal zullen de huidige aandeelhouders van Mallinckrodt 50,5 procent van de gefuseerde onderneming in handen hebben, die van Questcor 49,5 procent. Het bod ligt ruim een kwart boven de beurswaarde van Questcor bij sluiting van de beurs op Wall Street vrijdagavond.
  16. forum rang 10 voda 7 april 2014 21:04
    Op het fusie-en overnamefront was wel nieuws te melden. De farmaceut Mallinckrodt wil branchegenoot Questcor inlijven en legt daarvoor 5,6 miljard dollar (4,1 miljard euro) in contanten en eigen aandelen op tafel. Beleggers hielden nog een slag om de arm. Het aandeel Questcor steeg 14 procent maar bleef met ruim zo'n 77 dollar ruim onder de geboden prijs van 86,10 dollar. Mallinckrodt leverde 6,5 procent in.

    www.belegger.nl/nieuws/2648921/opnieu...
  17. forum rang 10 voda 8 april 2014 16:37
    Miljardenboete voor Japanse farmaceut Takeda

    TOKIO (Dow Jones)--Een Amerikaanse jury in de staat Louisiana heeft besloten dat de Japanse farmaceut Takeda Pharmaceutical Co. (4502.TO) $6 miljard aan schadevergoedingen moet betalen in een strafrechtelijk zaak, waarin het bedrijf wordt beschuldigd van het bewust achterhouden van informatie over de risico's van langdurig gebruik van zijn Actos diabetes medicijn.

    Langdurig gebruik zou de kans op blaaskanker vergroten met 40%.

    Naast Takeda betaalt het Amerikaanse Eli Lilly & Co (LLY) $3 miljard aan schadevergoedingen.

    In een reactie heeft het Japanse bedrijf dinsdag aaangegeven dat men de uitspraak gaat aanvechten.

    "Takeda is het niet eens met de uitspraak, en we zijn van plan deze daadkrachtig aan te vechten via alle beschikbare juridische middelen, bijvoorbeeld door in beroep te gaan", aldus Kenneth D. Greisman, de senior vice-president van de Amerikaanse unit van Takeda.

    Het aandeel van de Japanse farmaceut verloor dinsdag aan de Nikkei ruim 5%.

    Door Hiroyuki Kachi; vertaald en bewerkt door Marleen Groen; Dow Jones Nieuwsdienst; +31 20 5715 200; marleen.groen@wsj.com


  18. [verwijderd] 8 april 2014 20:14
    Leids TI Pharma op eigen benen
    LEIDEN - Het Leidse topinstituut TI Pharma verbreedt zijn rol. Van landelijke aanjager van farmaceutisch onderzoek is het uitgegroeid tot internationale consortiabouwer.
    TI Pharma op het Leidse Bio Science Park betreedt een nieuw tijdperk. Gedreven door de opdracht medicijnenonderzoek te versterken en te versnellen, richt het topinstituut zich niet meer alleen op de rijksoverheid die het in 2006 in het leven riep. Het is die schaal ook ontgroeid. ,,Wat landelijk begon, is nu heel erg internationaal. We zijn wereldwijd aan het koppelen’’, zegt zakelijk directeur Jorg Janssen. Om internationaal te kunnen overleven, en om nog beter werk te kunnen leveren, fuseert TI Pharma binnenkort met een ander topinstituut, het Center for Translational Molecular Medicine (CTMM) in Eindhoven.Meer over dit onderwerp
    *
  19. [verwijderd] 9 april 2014 15:51
    Experimental drug shows promise for treatment-resistant leukemias
    WEDNESDAY, 09 APRIL 2014 E-mailPrintPDF
    Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well as or better than similar drugs in head-to-head comparisons.
    More than 35 percent of acute myeloid leukemia (AML) patients harbor a mutation in the gene FMS-like tyrosine kinase-3 (FLT3). Normal FLT3 genes produce an enzyme that signals bone marrow stem cells to divide and replenish. But when FLT3 is mutated in some AML patients, the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition likely to relapse after treatment.

    Many investigators are developing and testing drugs designed to block the FLT3 enzyme's proliferation, several of which are now in clinical trials. So far, their effectiveness has been limited, according to Donald Small, M.D., Ph.D., the Kyle Haydock Professor of Oncology and director of pediatric oncology at Johns Hopkins. Small led a team of researchers who originally cloned the FLT3 gene and linked it to leukemia a decade ago.

    "We're very excited about TTT-3002, because it appears in our tests so far to be the most potent FLT3 inhibitor to date," says Small. "It showed activity against FLT3-mutated cells taken from patients and with minimal toxicity to normal bone marrow cells, making it a promising new candidate for the treatment of AML."

    In a series of experiments with the drug, Small, postdoctoral fellow Hayley Ma, Ph.D., and others found that the amount of TTT-3002 needed to block FLT3 activity in human leukemia cell lines was six- to sevenfold lower than for the most potent inhibitor currently in clinical trials. TTT-3002 also inhibited proteins made by genes further down the FLT3 signaling pathway, including STAT5, AKT and MAPK, and showed activity against the most frequently occurring FLT3 mutations, FLT3/ITD and FLT3/D835Y. Many cancer drugs are currently ineffective against FLT3/D835Y mutations.

    When the Johns Hopkins team tested the drug in a mouse model of leukemia, they found that it not only eliminated the presence of leukemic cells within 10 days of treatment but also that the mice lived an average of more than 100 days following treatment, to study completion, and resumed normal bone marrow activity. By contrast, mice treated with a placebo died an average of 18 days following treatment.

    Additional studies found that TTT-3002 performed as well as sorafenib, another FLT3 inhibitor, in treating leukemic mice, and that the drug was toxic to leukemia cell samples taken from newly diagnosed and relapsed patients with AML but did not affect normal bone marrow cells taken from healthy donors.

    A single dose of the medication caused more than 90 percent inhibition against FLT3 signaling that lasted for 12 hours, Small says.
6.458 Posts
Pagina: «« 1 ... 90 91 92 93 94 ... 323 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

De markt kijkt niet verder dan zijn neus lang is bij Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 31 mei Slotcall: AEX struikelt voor de finish, maar Pharming komt met de schrik vrij
  2. 31 mei Tegenslag bij EMA resulteert in tijdverlies voor Pharming 1
  3. 30 mei Europese goedkeuring voor leniolisib van Pharming loopt vertraging op 1
  4. 21 mei Jaarvergadering Pharming akkoord met alle agendapunten 1
  5. 10 mei RBC verlaagt koersdoel Pharming
  6. 08 mei Update: Flinke omzetstijging Pharming 2
  7. 08 mei AEX houdt 900 punten waarschijnlijk niet vast, zorgen Ahold, Pharming en SBM voor spektakel? 2
  8. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  9. 18 apr Pharming rondt plaatsing obligaties af 5
  10. 18 apr Pharming vervangt converteerbare lening 6

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!